Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download Full Day's HansardDownload Full Day's Hansard    View Or Save XMLView/Save XML

Previous Fragment    Next Fragment
Thursday, 23 March 1961

Mr Whitlam m asked the Minister for Health, upon notice -

1.   At which of its meetings did the Pharmaceutical Benefits Advisory Committee advise that androstanolone be (a) provided as a pharmaceutical benefit and (b) transferred to the restricted use category?

2.   When will the change (a) be notified in the "Gazette" and (b) come into operation?

Dr Donald Cameron (OXLEY, QUEENSLAND) - The answers to the honorable member's questions are as follows: -

1.   In accordance with the policy of treating the committee's recommendations as confidential to the Minister, this information is regarded as confidential.

2.   An amendment to the National Health (Pharmaceutical Benefits) Regulations, whereby the prescribing of androstanolone as a pharmaceutical benefit was restricted to certain specified purposes, was notified in" Gazette" No. 85a of 19th December, 1960, and came into operation on 1st January, 1961.

Suggest corrections